At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMVT Immunovant, Inc.
Post-Mkt 02-03 17:12:00 EST
25.80
-0.28
-1.07%
盘后25.80
+0.000.00%
16:15 EST
High26.82Low25.51Vol981.01K
Open26.07D1 Closing26.08Amplitude5.00%
Mkt Cap5.20BTradable Cap2.42BTotal Shares201.48M
T/O25.40MT/O Rate1.04%Tradable Shares93.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Immunovant, Inc. this quarter’s revenue is expected to increase by 0.00%, and institutional views are bullish
Earnings Agent  ·  01-30
Earning Preview: Immunovant, Inc. this quarter’s revenue is expected to increase by 0.00%, and institutional views are bullish
Immunovant Inc. to Announce Third Quarter Financial Results and Business Update
Reuters  ·  01-26
Immunovant Inc. to Announce Third Quarter Financial Results and Business Update
Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares
Reuters  ·  01-15
Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares
Immunovant price target raised to $22 from $16 at Truist
TIPRANKS  ·  01-08
Immunovant price target raised to $22 from $16 at Truist
Immunovant Raised to Outperform From Peer Perform by Wolfe Research
Dow Jones  ·  01-06
Immunovant Raised to Outperform From Peer Perform by Wolfe Research
Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares
Reuters  ·  2025-12-30
Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares
Immunovant (IMVT): Reassessing Valuation After a $550 Million Follow-On Equity Raise
Simply Wall St.  ·  2025-12-21
Immunovant (IMVT): Reassessing Valuation After a $550 Million Follow-On Equity Raise
Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant Sciences - What's Changed
Simply Wall St.  ·  2025-12-15
Immunovant (IMVT) Is Up 14.0% After $550 Million Follow-On Backed By Roivant Sciences - What's Changed
Immunovant (IMVT): Reassessing Valuation After $550 Million Follow-On Offering for IMVT-1402 Launch
Simply Wall St.  ·  2025-12-12
Immunovant (IMVT): Reassessing Valuation After $550 Million Follow-On Offering for IMVT-1402 Launch
Immunovant Inc - Files for Offering of 26,200,000 Shares of Common Stock - SEC Filing
THOMSON REUTERS  ·  2025-12-12
Immunovant Inc - Files for Offering of 26,200,000 Shares of Common Stock - SEC Filing
Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares
Reuters  ·  2025-12-12
Roivant Sciences President and Immunovant CEO Eric Venker Reports Disposal of Common Shares
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Benzinga_recent_news  ·  2025-12-12
Roivant Signals Major Pipeline Momentum With Accelerated Timelines
Roivant Sciences Fast-Tracks Key Drug Development Programs
MT Newswires Live  ·  2025-12-11
Roivant Sciences Fast-Tracks Key Drug Development Programs
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday as Oracle Results Sour Investor Mood
MT Newswires Live  ·  2025-12-11
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday as Oracle Results Sour Investor Mood
Immunovant Inc - Offers 26.2 Mln Shares at $21.00 per Share
THOMSON REUTERS  ·  2025-12-11
Immunovant Inc - Offers 26.2 Mln Shares at $21.00 per Share
Press Release: Immunovant Announces Pricing of $550 Million Common Stock Financing
Dow Jones  ·  2025-12-11
Press Release: Immunovant Announces Pricing of $550 Million Common Stock Financing
Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure
Simply Wall St.  ·  2025-11-26
Immunovant (IMVT): Assessing Valuation Following R&D Leadership Restructuring and CMO Departure
Immunovant Chief Medical Officer Michael Geffner Steps Down
MT Newswires Live  ·  2025-11-21
Immunovant Chief Medical Officer Michael Geffner Steps Down
Immunovant Chief Medical Officer Michael Geffner Departs Amid R&D Restructuring
Reuters  ·  2025-11-21
Immunovant Chief Medical Officer Michael Geffner Departs Amid R&D Restructuring
J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)
TIPRANKS  ·  2025-11-21
J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)

Introduction

Company Name.
Immunovant, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Issue price:
--